Great Novel Therapeutics Biotech & Medicals (ROCO:7427) ROE % Adjusted to Book Value : -2.10% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals ROE % Adjusted to Book Value?

Great Novel Therapeutics Biotech & Medicals's ROE % for the quarter that ended in Dec. 2023 was -8.73%. Great Novel Therapeutics Biotech & Medicals's PB Ratio for the quarter that ended in Dec. 2023 was 4.15. Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 was -2.10%.

Great Novel Therapeutics Biotech & Medicals ROE % Adjusted to Book Value Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals ROE % Adjusted to Book Value Chart

Great Novel Therapeutics Biotech & Medicals Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-4.89

-3.87

-3.03

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
ROE % Adjusted to Book Value	Get a 7-Day Free Trial					-3.82	-6.94	-3.95	-2.30	-2.10

Competitive Comparison of Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value falls into.

Great Novel Therapeutics Biotech & Medicals ROE % Adjusted to Book Value Calculation

Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-12.57%	/	4.15
	=	-3.03%

Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-8.73%	/	4.15
	=	-2.10%

Great Novel Therapeutics Biotech & Medicals ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503

Website

http://www.gntbm.com.tw

Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines